NanO2 may assist in mitigating secondary cellular brain damage after traumatic brain injury.

The design for an efficient Phase IIb clinical trial in stroke to test DDFPe in patients with Large Vessel Occlusions.

Although small, this trial shows that DDFPe used as a radiosensitizer appears to be safe and may provide some survival benefit.

This randomized, placebo-controlled, double-blind, dose-escalation clinical trial in acute ischemic stroke patients was designed to...

DDFPe treatment in rats with myocardial infarction was associated by significantly reduced ischemia-reperfusion injury.

Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...

DDFPe efficiently offloads oxygen to hypoxic environments. Link to publication

Animal studies, for both hemorrhagic shock and TBI, show promising effects of DDFPe as a resuscitation fluid.

In this swine model of TBI, administration of DDFPe resulted in lower injury scores for spongiosis and ischemic neurons.